Intellia Therapeutics Inc. Watch

from 10-Q 19 pages Employment Agreement

from 10-Q 5 pages Intellia Therapeutics, Inc. Seventh Amended and Restated Non-Employee Director Compensation Policy

from 8-K 34 pages Intellia Therapeutics, Inc. 2024 Inducement Plan

from 8-K 18 pages Employment Agreement

from 10-Q 5 pages Intellia Therapeutics, Inc. Sixth Amended and Restated Non-Employee Director Compensation Policy

from 10-K 7 pages Intellia Therapeutics, Inc. Second Amended Restated Corporate Bonus Plan

from 10-Q 26 pages Third Amendment to License and Collaboration Agreement

from 10-Q 7 pages Portions of This Exhibit Have Been Redacted Because They Are Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”

from 10-Q 23 pages First Amendment to Lease

from 10-K 5 pages The Intellia Therapeutics, Inc. (“Intellia” or the “Company”) Amended and Restated Retirement Policy for Equity Awards (The “Policy”) Is Intended to Retain Employees to Achieve Corporate Objectives Which Align With the Interests of Stockholders and to Also Encourage Employees to Provide Adequate Notice of Transition Prior to Retirement From the Company. 2. Applicability This Policy Applies to All Equity Awards, Including, Without Limitation, Options and Rsus (Each Defined Below) Granted to Employees After the Initial Effective Date of This Policy (“Eligible Equity Awards”). 3. Definitions “Award Agreement” Means a Written Agreement Entered Into Between the Company and an Employee or Other Documentation Issued by the Company to Such Employee, in Either Case Setting Forth the Terms of an Equity Award. “Committee” Means the Compensation and Talent Development Committee of the Board of Directors of the Company. “Final Exercise Date” Means the Final Date on Which a Retiree May Exercise Any Stock Options

from 10-Q 6 pages Target Bonus Award = Annual Base Salary X Target Bonus Percentage X

from 10-Q 5 pages The Intellia Therapeutics, Inc. (“Intellia” or the “Company”) Retirement Policy for Equity Awards (The “Policy”) Is Intended to Retain Employees to Achieve Corporate Objectives Which Align With the Interests of Stockholders and to Also Encourage Employees to Provide Adequate Notice of Transition Prior to Retirement From the Company. 2. Applicability This Policy Applies to All Equity Awards, Including, Without Limitation, Options and Rsus (Each Defined Below) Granted to Employees Other Than the Company’s Chief Executive Officer After the Initial Effective Date of This Policy (“Eligible Equity Awards”). 3. Definitions “Award Agreement” Means a Written Agreement Entered Into Between the Company and an Employee or Other Documentation Issued by the Company to Such Employee, in Either Case Setting Forth the Terms of an Equity Award. “Committee” Means the Compensation and Talent Development Committee of the Board of Directors of the Company. “Final Exercise Date” Means the Final Date on Which a Retiree May Exercise Any Stock Options

from 10-Q 87 pages License and Collaboration Agreement by and Between Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. April 11, 2016

from 10-Q 5 pages Intellia Therapeutics, Inc. Fifth Amended and Restated Non-Employee Director Compensation Policy

from 10-K 73 pages Lease Agreement

from 10-K 75 pages Certain Confidential Information Marked by [***] Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential

from 10-K 40 pages Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement for a Programmable Dna Restriction Enzyme for Genome Editing Uc Case No: Bk-2012-115 Crispr Reference: Charpentier-2012 Caribou Reference: Uc-Uv Agreement

from 8-K 5 pages Amendment #3 to License and Collaborative Research Agreement

from 10-Q 4 pages Intellia Therapeutics, Inc. Fourth Amended and Restated Non-Employee Director Compensation Policy

from 10-Q 46 pages License and Collaborative Research Agreement